Biofrontera Inc. (BFRI) Q3 Revenue Rose 29.8% to $9.1M

Q3 net product revenue rose 29.8% year over year to $9.1M; net loss was $6.4M versus $6.6M. Gross margin increased to 74.4% from 70.7%.Material DetailsContext by AI AnalystThis is an early commercial update following September FDA approval for Ameluz in superficial basal cell carcinoma and clearanc…